• Early indications for clinically significant efficacy during IPL344 treatment of ALS patients (ALSFRS-R and SVC)
• IPL344 established a favorable safety and tolerability profile
• A biomarker demonstrated that daily IPL344 treatment restored normal Akt

Jerusalem, Israel, February 2^nd 2020 – Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today that its novel ALS targeting drug IPL344 was granted an orphan drug designation by both the FDA (US Food and Drug Administration)

Jerusalem, Israel, August 14 2018 – Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today the initiation of a Phase 1/2a clinical trial of IPL344 in patients with amyotrophic lateral sclerosis (ALS) The trial is held at the ALS unit

Jerusalem, Israel, February 6, 2018 – Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today that the Israel's Ministry of Health (MOH) has approved the clinical protocol for its extended Phase 2a Amyotrophic Lateral Sclerosis (ALS)

Jerusalem, Israel, October 1, 2017 - Immunity Pharma, a privately-held neurology-focused biopharmaceutical company, announced today that Mr. Ron Pfeifer was appointed as the chairman of its Board of Directors, after serving as a director since 2015. Mr. Pfeifer is an

Jerusalem, Israel, July 27, 2017 - Immunity Pharma, a neurology-focused biopharmaceutical company, announced today that Dr. Ilana Cohen has joined Immunity Pharma as its Vice President of Research and Development. Dr. Cohen earned her PhD in neurobiology from the Weismann

Jerusalem, Israel, December 1, 2016 - Immunity Pharma, a neurology-focused biopharmaceutical company, announced today that it has passed a two-year mark for treating an ALS patient with IPL344 under a companionate treatment protocol. This ALS patient has been treated with